1. Academic Validation
  2. Evaluation of brain pharmacokinetics of (+)MK-801 in relation to behaviour

Evaluation of brain pharmacokinetics of (+)MK-801 in relation to behaviour

  • Neurosci Lett. 2011 Sep 26;503(1):68-72. doi: 10.1016/j.neulet.2011.08.012.
Nico Wegener 1 Jens Nagel Ralph Gross Caroline Chambon Sergio Greco Malgorzata Pietraszek Andreas Gravius Wojciech Danysz
Affiliations

Affiliation

  • 1 Merz Pharmaceuticals GmbH, Dept. In vivo Pharmacology, Alfred-Wegener-Strasse 2, D-60438 Frankfurt am Main, Germany. nico.wegener@merz.de
Abstract

The non-competitive N-methyl-d-aspartate (NMDA) receptor antagonist (+)MK-801 is widely used in animal research (over 3000 publications), however its extracellular brain concentration has never been reported. Here, we show using in vivo microdialysis that systemic injection of (+)MK-801 at doses of 0.05, 0.1 or 0.2mg/kg resulted in peak brain ECF concentration of 6, 14 or 34 nM, respectively. Moreover, (+)MK-801 resulted in a dose-dependent learning impairment in the Morris water maze as well as hyperactivity in the open field. These data demonstrate for the first time that (+)MK-801 at doses producing behavioural alterations expected from NMDA Receptor blockade reaches extracellular brain concentrations corresponding to the affinity at NMDA receptors.

Figures
Products